Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 9

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
, results of operations, and cash flows, or do not apply to its operations.

In December 2023, the FASB issued ASU No. 2023-09,
“Improvements to Income Tax Disclosures”, which requires disclosure of disaggregated income taxes paid, prescribes standard
categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09
is effective for the Company’s Annual Report om Form 10-K for the year ended December 31, 2025.
Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated
financial statements, the Company expects changes to the Company’s income tax disclosure.

In November 2024, the FASB issued Accounting Standards
Update No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures: Disaggregation
of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of
expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative
expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will
have on the Company’s disclosures.

Note 4. Net Loss per Common Share

Basic and diluted net loss per common share was computed
by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during
each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding
in periods where there is a net loss, as their effect is anti-dilutive.

The total number of shares of common stock issuable
upon exercise of warrants, stock option grants and equity awards were 7,137,111 and 1,197,390 shares for the periods ended March 31, 2025
and 2024, respectively. For the three-month periods ended March 31, 2025 and 2024, diluted loss per common share was the same as basic
loss per common share as the other warrants, and equity awards that were convertible into shares of the Company’s common stock were
excluded from